Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
In conclusion, FLU/BU4/MEL showed curative potential, even in patients with advanced myeloid malignancies, accompanied by achievement of rapid complete chimerism after allo-BMT/PBSCT.
PMID: 30448938 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - Category: Hematology Authors: Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y Tags: Int J Hematol Source Type: research
More News: Bone Marrow Transplant | Cancer & Oncology | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants